Display options
Share it on

J Atr Fibrillation. 2016 Oct 31;9(3):1502. doi: 10.4022/jafib.1502. eCollection 2016.

Amiodarone-Induced Third Degree Atrioventricular Block and Extreme QT Prolongation Generating Torsade Des Pointes in Paroxysmal Atrial Fibrillation.

Journal of atrial fibrillation

Orlando Robert Sequeira, Nelson Javier Aquino, Nancy Beatriz Gómez, Laura Beatriz García, Cristina Cáceres, Oscar A Lovera, Osmar Antonio Centurión

Affiliations

  1. Department of Health Sciences's Investigation. Sanatorio Metropolitano. Fernando de la Mora. Paraguay. Cardiology Department, Clinic Hospital, Asunción National University, San Lorenzo, Paraguay.

PMID: 28496937 PMCID: PMC5368557 DOI: 10.4022/jafib.1502

Abstract

Amiodarone is still the most potent antiarrhythmic drug in the prevention of life threatening ventricular arrhythmias and demonstrates a very low incidence of torsade de pointes. An unusual case of an 81-year-old woman who developed serious abnormalities of the conduction system of the heart and torsade des pointes during intravenous infusion of amiodarone for the treatment of paroxysmal atrial fibrillation is described. To the best of our knowledge, this is the first case showing an association of intravenous amiodarone-induced third degree atrioventricular block and extreme QT interval prolongation generating torsade des pointes in a patient with paroxysmal atrial fibrillation who required an implantable cardioverter-defibrillator. Currently, amiodarone is still one of the few remaining treatment options for the medical therapeutic management of serious ventricular arrhythmias and to reduce the incidence of atrial fibrillation without increasing mortality or sudden cardiac death rates in heart failure patients like our elderly present patient. Nevertheless, we have to keep in mind that intravenous amiodarone may generate serious abnormalities of the conduction system of the heart and lethal ventricular arrhythmias in certain patients.

Keywords: Amiodarone; Implantable Cardioverter-Defibrillator; Paroxysmal Atrial Fibrillation; QT Interval Prolongation; Third Degree AV Block; Torsade Des Pointes

References

  1. J Cardiovasc Pharmacol. 2004 Sep;44(3):278-86 - PubMed
  2. Circulation. 2006 Jul 11;114(2):104-9 - PubMed
  3. Lancet. 1997 Mar 8;349(9053):675-82 - PubMed
  4. Am Heart J. 1983 Oct;106(4 Pt 2):788-97 - PubMed
  5. N Engl J Med. 1995 Jul 13;333(2):77-82 - PubMed
  6. N Engl J Med. 1991 Mar 21;324(12):781-8 - PubMed
  7. JAMA. 2007 Sep 19;298(11):1312-22 - PubMed
  8. J Am Coll Cardiol. 1997 Sep;30(3):791-8 - PubMed
  9. Heart Rhythm. 2007 Sep;4(9):1250-9 - PubMed
  10. Circulation. 2001 Mar 6;103(9):1317-24 - PubMed
  11. Eur Heart J. 1986 Mar;7(3):234-9 - PubMed
  12. Lancet. 1997 Mar 8;349(9053):667-74 - PubMed
  13. Emerg Med J. 2008 Jan;25(1):15-8 - PubMed
  14. Ann Intern Med. 1994 Oct 1;121(7):529-35 - PubMed
  15. Heart Rhythm. 2006 Apr;3(4):484-7 - PubMed
  16. J Cardiovasc Pharmacol Ther. 2010 Dec;15(4 Suppl):24S-30S - PubMed
  17. Prog Cardiovasc Dis. 1989 Jan-Feb;31(4):249-80 - PubMed
  18. J Cardiovasc Electrophysiol. 1995 Oct;6(10 Pt 2):920-36 - PubMed

Publication Types